Publications by authors named "Scott A Monk"

Claim this Profile
R
Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species.
Brian A Willis, Stephen L Lowe, Scott A Monk, Patrick J Cocke, Christopher D Aluise

J Alzheimers Dis Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
David L McKinzie, Leonard L Winneroski, Steven J Green, Erik J Hembre, Jon A Erickson, Scott A Monk

J Med Chem· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.
Scott A Monk, Alan R Kugler, Scott W Andersen, Mosun A Ayan-Oshodi, Douglas E James

J Clin Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Brian A Willis, Scott W Andersen, Mosun Ayan-Oshodi, Douglas E James, Emily Liffick, Scott A Monk

J Clin Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Leonard L Winneroski, Jon A Erickson, Steven J Green, Jose E Lopez, Stephanie L Stout, Scott A Monk

Bioorg Med Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.
Naidong Ye, Scott A Monk, Pankaj Daga, David M Bender, Laura B Rosen

Clin Pharmacol Drug Dev· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS.
Yan Li, Paul H Severin, Mark R Hoffmann, Dennis L Miller, Scott A Monk

Bioanalysis· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
Leonard L Winneroski, Matthew A Schiffler, Jon A Erickson, Patrick C May, Scott A Monk

Bioorg Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
Patrick C May, Brian A Willis, Stephen L Lowe, Robert A Dean, Scott A Monk

J Neurosci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
Patrick C May, Robert A Dean, Stephen L Lowe, Ferenc Martenyi, Scott M Sheehan, Scott A Monk

J Neurosci· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible stepwise negative regulation of CYP1A1 in cultured rat epidermal cells.
Scott A Monk, Michael S Denison, Robert H Rice

Arch Biochem Biophys· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis